| Literature DB >> 33758816 |
Zeynep Çetin1, Rıdvan Mercan2, Ömer Karaşahin3, Abdurrahman Tufan4, Mehmet Akif Öztürk4.
Abstract
OBJECTIVES: This study aims to determine the frequency and risk factors of bacteriuria and urinary tract infection (UTI) in patients with primary Sjögren's syndrome (SS) and their differences from healthy individuals and rheumatoid arthritis (RA) patients. PATIENTS AND METHODS: The study included 107 female primary SS patients (mean age 50.7±11.6 years; range, 23 to 76 years), 53 healthy female control subjects (mean age 46.8±15.5 years; range 21 to 80 years), and 40 females with RA (mean age 51.7±14.2 years; range, 25 to 79 years). Participants were questioned for UTI risk factors and symptoms. Middle stream urine samples were taken and cultured. All participants were examined with urinary symptom questioning survey of American Urological Association (AUA-7).Entities:
Keywords: Bacteriuria; Sjögren’s syndrome; infection; urinary tract
Year: 2020 PMID: 33758816 PMCID: PMC7945699 DOI: 10.46497/ArchRheumatol.2020.7427
Source DB: PubMed Journal: Arch Rheumatol ISSN: 2148-5046 Impact factor: 1.472
American-European Consensus Group’s international classification criteria for primary Sjögren’s syndrome
| I. Ocular symptoms: a positive response to at least one of the following questions: |
| 1. Have you had daily, persistent, troublesome dry eyes for more than three months? |
| 2. Do you have a recurrent sensation of sand or gravel in the eyes? |
| 3. Do you use tear substitutes more than three times a day? |
| II. Oral symptoms: a positive response to at least one of the following questions: |
| 1. Have you had a daily feeling of dry mouth for more than three months? |
| 2. Have you had recurrently or persistently swollen salivary glands as an adult? |
| 3. Do you frequently drink liquids to aid in swallowing dry food? |
| III. Ocular signs-that is, objective evidence of ocular involvement defined as a positive result for at least one of the following two tests: |
| 1. Schirmer’s I test, performed without anaesthesia (<5 mm in 5 minutes) |
| 2. Rose Bengal score or other ocular dye score (>4 according to van Bijsterveld’s scoring system) |
| IV. Histopathology: In minor salivary glands (obtained through normal-appearing mucosa) focal lymphocytic sialoadenitis, evaluated by an expert histopathologist, with a focus score >1, defined as a number of lymphocytic foci (which are adjacent to normal-appearing mucous acini and contain more than 50 lymphocytes) per 4 mm2 of glandular tissue |
| V. Salivary gland involvement: objective evidence of salivary gland involvement defined by a positive result for at least one of the following diagnostic tests: |
| 1. Unstimulated whole salivary flow (<1.5 mL in 15 minutes) |
| 2. Parotid sialography showing the presence of diffuse sialectasis (punctate, cavitary or destructive pattern), without evidence of obstruction in the major ducts |
| 3. Salivary scintigraphy showing delayed uptake, reduced concentration and/or delayed excretion of tracer |
| VI. Autoantibodies: presence in the serum of the following autoantibodies: |
| 1. Antibodies to Ro(SSA) or La(SSB) antigens, or both |
| Ro(SSA): Sjögren’s syndrome type A; La(SSB): Sjögren’s syndrome type B. |
American College of Rheumatology/European League Against Rheumatism 2010 classification criteria for rheumatoid arthritis
| Target population (Who should be tested?): Patients | |
| 1) who have at least one joint with definite clinical synovitis (swelling)* | |
| 2) with the synovitis not better explained by another disease† | |
| Classification criteria for RA (score-based algorithm: add score of categories A-D; a score of 6/10 is needed for classification of a patient as having definite RA)‡ | |
| A. Joint involvement§ | |
| 1 large joint¶ | 0 |
| 2-10 large joints | 1 |
| 1-3 small joints (with or without involvement of large joints)# | 2 |
| 4-10 small joints (with or without involvement of large joints) | 3 |
| >10 joints (at least 1 small joint)** | 5 |
| B. Serology (at least one test result is needed for classification)†† | |
| Negative RF and negative ACPA | 0 |
| Low-positive RF or low-positive ACPA | 2 |
| High-positive RF or high-positive ACPA | 3 |
| C. Acute-phase reactants (at least one test result is needed for classification)‡‡ | |
| Normal CRP and normal ESR | 0 |
| Abnormal CRP or abnormal ESR | 1 |
| D. Duration of symptoms§§ | |
| <6 weeks | 0 |
| >6 weeks | 1 |
| RA: Rheumatoid arthritis; RF: Rheumatoid factor; ACPA: Anticitrullinated protein antibody; CRP: C-reactive protein; ESR: Erythrocyte sedimentation rate. | |
Characteristics of study participants
| Primary SS (n=107) | Rheumatoid arthritis (n=40) | Control (n=53) | ||||||||||
| n | % | Mean±SD | Min-Max | n | % | Mean±SD | Min-Max | n | % | Mean±SD | Min-Max | |
| Age (year) | 50.7±11.6 | 23-76 | 51.7±14.2 | 25-79 | 46.8±15.5 | 21-80 | ||||||
| Sex | ||||||||||||
| Female | 107 | 100 | 40 | 100 | 53 | 100 | ||||||
| Comorbidity | ||||||||||||
| Hypertension | 35 | 32.7 | 10 | 25 | 17 | 32 | ||||||
| Thyroid dysfunction | 22 | 22.5 | 0 | 0 | 11 | 20.7 | ||||||
| Hyperlipidemia | 7 | 6.5 | 0 | 0 | 2 | 3.7 | ||||||
| Coronary artery disease | 2 | 1.86 | 1 | 2.5 | 2 | 3.7 | ||||||
| Asthma | 1 | 1.07 | 1 | 2.5 | 4 | 7.5 | ||||||
| Autoimmune hepatitis | 2 | 1.86 | 0 | 0 | 0 | 0 | ||||||
| Depression | 1 | 1.07 | 0 | 0 | 3 | 5.6 | ||||||
| SD: Standard deviation; Min: Minimum; Max: Maximum; SS: Sjögren’s syndrome. | ||||||||||||
Clinical and serologic findings of patients with primary Sjögren’s syndrome at time of diagnosis
| n | % | Mean±SD | Min-Max | |
| Symptom duration (year) | 5.6±3.8 | 1-23 | ||
| Xerostomia | 72 | 67.3 | ||
| Xerophthalmia | 81 | 75.7 | ||
| Vaginal dryness | 19 | 17.8 | ||
| Skin dryness | 31 | 29.0 | ||
| Joint complaint | 100 | 93.5 | ||
| Peripheral nervous system involvement | 10 | 9.3 | ||
| Central nervous system involvement | 1 | 0.9 | ||
| Pulmonary involvement | 2 | 1.86 | ||
| Renal involvement | 2 | 1.86 | ||
| Steroid usage | 12 | 11.2 | ||
| Sedimentation (mm/h) | 36.9±1.9 | 5-91 | ||
| C-reactive protein (mg/L) | 8.4±1.1 | 0-59 | ||
| Rheumatoid factor positivity | 68 | 63.5 | ||
| ANA positivity | 101 | 94.4 | ||
| Anti-Ro (SSA) positivity | 68 | 63.5 | ||
| Anti-Ro 52 positivity | 70 | 65.4 | ||
| Anti-La (SSB) positivity | 41 | 38.3 | ||
| Schirmer | ||||
| Mild (10-15 mm/5 min) | 20 | 18.7 | ||
| Moderate (5-10 mm/5 min) | 28 | 26.2 | ||
| Advanced (<5 mm/5 min) | 29 | 27.1 | ||
| Focus score | ||||
| 0 | 11 | 10.3 | ||
| 1 | 37 | 34.5 | ||
| 2 | 32 | 29.9 | ||
| 3 | 22 | 20.5 | ||
| SD: Standard deviation; Min: Minimum; Max: Maximum; ANA: Antinuclear antibody; Anti-Ro (SSA): Anti- Sjögren’s syndrome type A; Anti-La (SSB): Anti-Sjögren’s syndrome type B. | ||||
Comparison of the groups for age, risk factor, number of UTI within the last six months, leucocyturia and number of positive culture
| Primary SS (n=107) | Rheumatoid arthritis (n=40) | Control (n=53) | |||||||||||
| n | % | Mean±SD | Min-Max | n | % | Mean±SD | Min-Max | n | % | Mean±SD | Min-Max | ||
| Age (year) | 50.7±11.6 | 51.7±14.2 | 25-79 | 46.8±15.5 | 21-78 | NS | |||||||
| Risk factors | 17 | 10 | 7 | NS | |||||||||
| Average number of UTIs in last six months | 27* | 4 | 5 | 0.013 | |||||||||
| Leukocyturia** | 21 | 19.6 | 14 | 35 | 17 | 32 | NS | ||||||
| Number of positive | 18 | 16.8 | 8 | 20 | 2 | 3.7 | 0.04 | ||||||
| SD: Standard deviation; Min: Minimum; Max: Maximum; SS: Sjögren’s syndrome; * This difference was due to SS; ** Leukocyturia: leukocyte >5/high power field. | |||||||||||||
Comparison of three groups of AUA-7 scores
| SS (n=107) | RA (n=40) | Control (n=53) | ||
| Median±IQR | Median±IQR | Median±IQR | ||
| AUA-7 | 4±6 | 3±8 | 2±4 | 0.08 |
| AUA-7: Urinary system symptom questionnaire; SS vs control p=0.031, RA vs control p=0.073. | ||||